Abstract
The traditional model of innovation in the pharmaceutical industry is being challenged by an explosion of costs for R&D, a strengthened voice of the customer and regulatory bodies in the development of new medicines, and the vanishing of easy targets. An overview is given of established and emerging pharma companies, the cost structures for pharma innovation, and the nature of the productivity gap. We describe the blockbuster imperative and the pervasive concerns about risk and safety in pharma R&D, and conclude with a brief outlook on the main themes to be discussed in the remainder of the book.
“… lasting innovation is our biggest gift to society.”
Dr. Severin Schwan,
CEO Roche
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
As is customary, all names of medicines, drugs and product labels should be considered as trademarked. We have no commercial interest in any of the companies or their products mentioned in the book.
Bibliography
European Commission. (2014). The 2014 EU Industrial R&D investment scoreboard. European Commission—Joint Research Centre. http://iri.jrc.ec.europa.eu/scoreboard.html. Accessed 8 June 2016.
European Commission. (2015). The 2015 EU Industrial R&D investment scoreboard. European Commission—Joint Research Centre. http://iri.jrc.ec.europa.eu/scoreboard15. Accessed 8 June 2016.
Evaluate. (2015). World preview 2015, outlook to 2020. http://info.evaluategroup.com/rs/607-YGS-364/images/wp15.pdf. Accessed 15 Feb 2016.
Grabowski, H., Vernon, J., & DiMasi, J. A. (2002). Returns on research and development for 1990s new drug introductions. Pharmacoeconomics, 20, 11–29.
Mullard, A. (2016). 2015 FDA drug approvals. Nature Reviews Drug Discovery, 15, 73–76.
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., et al. (2010). How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery, 9, 203–214.
Pharma Information. (2002). Swiss Health Care and pharmaceutical market. Edition 2002. Basel: Interpharma.
PhRMA. (2015). 2015 profile biopharmaceutical research industry. PhRMA website at http://www.phrma.org/sites/default/files/pdf/2015_phrma_profile.pdf. Accessed 20 June 2016.
Reuters. (2003a). The blockbuster drug outlook to 2007: Identifying, creating and maintaining the pharmaceutical industry’s growth drivers. Reuters Business Insight, Healthcare.
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 11, 191–200.
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016). Changing R&D models in research-based pharmaceutical companies. Journal of Translational Medicine, 14, 105–115.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Gassmann, O., Schuhmacher, A., von Zedtwitz, M., Reepmeyer, G. (2018). Innovation: Key to Success in the Pharmaceutical Industry. In: Leading Pharmaceutical Innovation. Springer, Cham. https://doi.org/10.1007/978-3-319-66833-8_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-66833-8_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-66832-1
Online ISBN: 978-3-319-66833-8
eBook Packages: Business and ManagementBusiness and Management (R0)